Adjunctive asenapine
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Posttraumatic Stress Disorder
Conditions
Posttraumatic Stress Disorder
Trial Timeline
Jun 1, 2012 → Jul 1, 2016
NCT ID
NCT01587118About Adjunctive asenapine
Adjunctive asenapine is a approved stage product being developed by Merck for Posttraumatic Stress Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01587118. Target conditions include Posttraumatic Stress Disorder.
What happened to similar drugs?
2 of 3 similar drugs in Posttraumatic Stress Disorder were approved
Approved (2) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01587118 | Approved | Completed |
Competing Products
8 competing products in Posttraumatic Stress Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 36 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 35 |
| Placebo + sertraline | Johnson & Johnson | Approved | 35 |
| sertraline (Zoloft) | Pfizer | Pre-clinical | 26 |
| Ziprasidone | Pfizer | Approved | 43 |
| Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg | Brain Biotech | Phase 2 | 17 |
| High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis | Tilray | Phase 2 | 29 |
| Riluzole | Brain Biotech | Phase 1 | 19 |